UK-US zero tariff pharma deal raises questions for India’s export position

In a significant boost to its life sciences industry, the United Kingdom has secured a 0 per cent tariff rate on all UK-origin medicines, ingredients and medical technology exported to the United States for at least the next three years. The agreement, confirmed by officials on Monday, forms part of a broader trade understanding under which the UK has committed to higher domestic spending on new medicines.

According to officials familiar with the negotiations, the US has agreed to exempt British pharmaceuticals and medical technology from import taxes, while UK-based drug manufacturers have committed to increase investment in the US and create additional jobs. Government sources said the tariff-free access granted to the UK is the lowest import tax rate offered by Washington to any country in the sector.

As part of the deal, the UK’s National Health Service will raise spending on new and effective treatments by about 25 per cent, marking the first major increase in such expenditure in more than two decades. This additional spending is expected to help approve therapies that may previously have been rejected solely on cost-effectiveness grounds including breakthrough oncology drugs and treatments for rare diseases.

Officials said it was emphasised that the deal “will ensure cutting-edge medicines reach UK patients sooner, and that world-leading UK firms continue developing life-changing treatments.”

The Association of the British Pharmaceutical Industry (ABPI) noted in a statement that the agreement was regarded as “a step towards enabling patient access to innovative medicines” and was viewed as strengthening the UK’s ability to attract long-term life sciences investment.

From the US side, it was maintained that the agreement “strengthens the global environment for innovation and brings balance to US-UK pharmaceutical trade.”

The deal comes at a time when several pharmaceutical giants including AstraZeneca have slowed or withdrawn investments in the UK amid concerns over regulatory delays and pricing pressures. US ambassador Warren Stephens recently warned that American businesses might scale back future investments unless rapid reforms were enacted.

The tariff decision aligns with a wider trade framework agreed earlier this year between President Donald Trump and UK Prime Minister Keir Starmer, under which the US committed to cutting import taxes on British cars, steel and aluminium in exchange for greater market access for American beef, ethanol and other products.

India, one of the world’s largest suppliers of generic medicines to the US, is expected to feel the ripple effects of the new UK-US tariff agreement, though analysts say the impact will differ across product segments. The UK’s strong R&D-focused pharmaceutical sector particularly in biologics, oncology drugs and advanced therapies could gain a competitive edge over Indian firms in high-value categories where tariffs still apply to other exporters.

However, India’s dominant position in the US generics market, which accounts for more than 40 per cent of American generic prescriptions, is unlikely to face significant disruption, as the UK does not compete directly in this volume-driven space. Some analysts warn that the influx of lower-cost UK-origin innovative drugs may subtly influence US procurement patterns and heighten pricing pressure on Indian companies trying to expand into complex generics and biosimilars. At the same time, the UK’s commitment to increase NHS spending on advanced treatments may open avenues for collaboration, with Indian manufacturers potentially benefiting from expanded contract production or R&D partnerships, given their established role as suppliers of ingredients and finished formulations to British firms.

Overall, while India’s core generics exports remain largely insulated, the changing tariff landscape highlights the need for Indian pharma to accelerate innovation, deepen investments in biologics and reinforce supply-chain resilience.